NEW FRONTIERS
IN NEUROSCIENCE
According to a recent article published in the Lancet in November 2021 entitled "Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic" (Vol: 398, Issue: 10312, Page: 1700-1712), it is estimated that an additional 53 million cases of major depressive disorder occurred globally as a result of the pandemic. The additional effect of the Ukraine war on global mental health hasn't yet been quantified but it is expected to be substantial.
Mental health conditions, such as major depressive disorder (MDD), anxiety disorders, post-traumatic stress disorder, schizophrenia, and a range of psychiatric disorders, are widely recognized as mood and cognitive disorders that lead to various emotional and physical challenges. These conditions are characterized by persistent feelings of sadness, anger, irritability or frustration, loss of interest in activities, and disruptions in daily life.
Current treatments often focus on increasing the levels of neuromediators in the brain synapses to improve these conditions, although the underlying causes remain complex and multifaceted. Treatments typically aim to slow down the reuptake of neuromediators, increasing their concentration in the synapses. In some cases, individuals do not respond well to available treatments, leading to treatment-refractory conditions marked by chronic impairment, disability, and social challenges. The impact of these conditions is substantial, affecting individuals and communities globally.
Mental health is an enhanced burden to society
Expertise, Experience, Innovation, Vision, Values.
Neurentis PLC is a UK biotech company, specialising in the development of novel treatments for neurological and psychiatric diseases.
Our product pipeline includes a transdermal patch in late-stage development, for Treatment-Resistant Depression, an AI-driven initiative to discover novel antidepressants, leveraging cutting-edge technology to identify optimal drug candidates for effective mental health support, and a drug which acts on the oxytocin receptors for autism, PTSD, anxiety, depression, schizophrenia, alcohol withdrawal, drug addiction and Prader-Willi Syndrome.
The company is run by experienced ex-pharma industry executives, with more than 30 years’ experience in the sector. Our low-risk commercial strategy is to commercialise our products through collaborations with pharma companies in various countries.
Pharma Market Potential
Global healthcare spending is expected to increase at an annual rate of 5.4% between 2017 to 2022, from USD 7.7 trillion to USD 10 trillion (Deloitte, 2019); among the major factors contributing to worldwide healthcare expenditures are ageing and growing populations, and the increasing prevalence of chronic diseases.
Learn More
Our Vision and Values
Our Vision, Values, Mission and Strategy are the foundation for our unique culture. These unify us in a common cause to improve the health of patients and lives of their families and other carers in a meaningful way by developing novel and innovative medicines and inspires us to make a positive contribution wherever we can.
OUR VISION: To provide new medicines of superior quality and value that improve the health of people suffering from serious diseases as well as the lives of their families and other carers.
OUR VALUES: Our fundamental values are of integrity alongside a desire to be honest and straightforward with one another. We are data-based and intellectually trustworthy while also recognising risks. We aspire to being leaders in our area of expertise, we have a clear vision of where we are going and focus our resources to achieve our objectives and strategies. We have a compelling desire to improve and to win in our sector We are a true partnership, ensuring we treat the company’s assets as our own while constantly having the company’s long term success in mind. We show respect for all, value differences and inspire achievement.
Understanding the Various Approaches to Treating Psychiatric Conditions
Mental health conditions, encompassing a wide range of disorders from depression and anxiety to schizophrenia and autism, present complex challenges in the field of healthcare. While significant progress has been made in developing drug treatments for many medical conditions, the landscape of mental health remains characterised by unmet needs.
Efficacy Variation: One significant challenge in mental health treatment is the variation in the efficacy of available drugs. While some individuals respond well to certain medications, others may not experience the same benefits. This variability underscores the need for more tailored and effective treatment options.
Side Effects: Many of the drugs used to treat mental health conditions can be associated with unwanted side effects, leading to issues of non-compliance and discontinuation of medication. Finding medications with fewer side effects is an ongoing challenge.
Incomplete Understanding: Unlike some physical health conditions where the mechanisms are well understood, the underlying causes of many mental health conditions remain complex and multifaceted. This lack of comprehensive understanding hampers the development of targeted drug therapies.
Behavioral and Psychological Interventions
Applied Behavior Analysis, Speech and Language Therapy, Occupational Therapy, Cognitive Behavioral Therapy, Mindfulness-Based Stress Reduction, Interpersonal Therapy, Psychodynamic Therapy, Psychotherapy.
Medications
Antipsychotic Medications (for managing challenging behaviors), Antidepressants, Benzodiazepines (for short-term relief), Antianxiety Medications, Mood Stabilizers.
Supportive and Lifestyle Interventions
Medical Detoxification, Support Groups, Medication-Assisted Treatment, Behavioral Therapy, Nutritional Management, Behaviour Modification, Growth Hormone Therapy, Exercise, Yoga, Meditation, Relaxation Techniques.
Physical and Invasive Therapies
Various neuropsychiatric conditions are being targeted by therapies such as neuromodulation techniques (e.g., Transcranial Magnetic Stimulation for depression) and experimental treatments. Research is ongoing.
Depressing facts and figures
Highlighting the needs in mental health